Search

Displaying results 3811 - 3820 of 10000 in total
  1. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.

  2. Drug

    Thioridazine

    go.drugbank.com/drugs/DB00679
    ApprovedWithdrawn

    Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618).

    Synonyms: 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine
  3. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    [L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770] … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.

  4. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  5. Drug

    Frangula purshiana bark

    go.drugbank.com/drugs/DB15478
    Approved

    Synonyms: Rhamnus purshiana bark dry extractMixtures: Herbalax Forte No 70 Tab
  6. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine.

    Synonyms: N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester
  7. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness.

  8. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.

  9. Drug

    D-Asparagine

    go.drugbank.com/drugs/DB03943
    Experimental

    A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase.

  10. Drug

    BI 4060107

    go.drugbank.com/drugs/DB33963
    Experimental

    BI 4060107 is under investigation in clinical trial NCT07827144 (A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)).